Out Fox The $treet

Updated - Feb. 21, 2025 Hims & Hers Health isn't reliant on GLP-1 shortages. Not sure why news reports keep making this false claim, but the stock is down 20% today on the FDA ending the semagultide shortage status.  -The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs for two more months as supply conditions for the GLP-1s improve after an official end to their shortage. -Earlier in the day, the agency declared that the nationwide shortage of the highly popular GLP-1s, collectively known as semaglutide, is resolved after nearly three years. -“The FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand,” the regulator said. -Hims & Hers (NYSE:HIMS), which made compounded versions of semaglutide amid the shortage, lost billions of dollars in market cap in reaction as the telehea...

Update - May 21  Hims has slumped some after the initial 30% rally on Monday. The telehealth company should benefit from offering a compound GLP-1 version at a discounted price. The big question is the financial impact. The stock only trades at 3x '24 sales targets making Hims intriguing on any further dip.  -Hims & Hers Health (NYSE:HIMS) is offering customers access to compounded versions of Novo Nordisk's (NVO) semaglutide -- the active drug in its weight loss medication Wegovy -- at a fraction of the cost of the brand-name version. -The company said plans for injections of its compounded semaglutide -- which is also sold as the type 2 diabetes med Ozempic -- start at $199 a month. It is also offering a $79 a month plan for an oral version of semaglutide. That is also known as Novo's diabetes pill Rybelsus. Original article posted on May 7 Hims & Hers Health, Inc. is leading in personalized health and building a strong health and wellness platform, leading to str...

Updated Aug. 23, 2023 Hims continues trending down. The stock remains appealing on these dips with software like margins and growth rates.  Update Aug. 17, 2023 Hims & Hers continues to dip following another great earnings report. The online health and wellness platform continues to shift towards profitable precisions treatments, but the market has missed the shift. Definitely a stock to watch for when Hims hits the lows.  Original article published on Aug. 16  Hims & Hers Health, Inc. falls despite a strong Q2 '23 earnings report. The company remains on the path to a 2025 revenue target of $1.2+ billion. The stock is cheap at 1.3x forward EV/S targets for a high gross margin business. Out Fox The Street members get exclusive access to our real-world portfolios. See all of our investments  here »   Despite another strong quarter,  Hims & Hers Health, Inc.  ( NYSE: HIMS ) stock fell after  Q2 '23 results  beat consensus estimates. ...

Out Fox The Street members get exclusive access to our real-world portfolios. See all of our investments  here »   Update - July 28, 2023  Cowen with a bull call on Hims with a price target of $11 after the stock recently traded at $12. Nice the greatest bull call, but it sure beats the short report.  TD Cowen initiated its coverage of the digital healthcare platform Hims & Hers Health ( NYSE: HIMS ) with an Outperform rating and a $11 per share target on Friday, citing a disconnect between the company’s prospects and the valuation. Noting that Hims & Hers ( HIMS ) is set to expand at over 78% CAGR in 2019–2023E, analyst Jonna Kim argues that the company’s $1.2B revenue target for 2025, indicating over 22% CAGR, "implies a significant slowdown." Update - July 13, 2023 Kinda of a joke short report on Hims & Hers today, any stock could face a 25% hit. Heck, we view Apple  as having the potential for 50% downside. The stock has bounced off strong suppor...